Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis

Peptides

Volumn 31, Issue 8, 2010, Pages 1511-1516

  Kristof, Arnold S ^a   You, Zhipeng ^a   Han, Yin Shan ^a   Giaid, Adel ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Human; Immunohistochemistry; UT; Western blotting

Indexed keywords

G PROTEIN COUPLED RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY HMB 45; NEUROPEPTIDE; PROTEIN HMB45; PROTEIN S6; TUBERIN; TUMOR MARKER; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN RECEPTOR; UROTENSIN RELATED PEPTIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; INFLAMMATORY CELL; LUNG ALVEOLUS EPITHELIUM; LUNG BLOOD VESSEL; LUNG INTERSTITIUM; LYMPHANGIOLEIOMYOMATOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

MAMMALIA;

EID: 78249242396     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2010.04.017     Document Type: Article

References (50)

1. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999;401:282-286
2. Behm DJ, Ao Z, Camarda V, Aiyar NV, Johns DG, Douglas SA. Inhibitory effects of putative peptidic urotensin-II receptor antagonists on urotensin-IIinduced contraction of cat isolated respiratory smooth muscle. Eur J Pharmacol 2005;516:276-281
3. Bern HA, Pearson D, Larson BA, Nishioka RS. Neurohormones from fish tails: the caudal neurosecretory system. I. "Urophysiology" and the caudal neurosecretory system of fishes. Recent Prog Horm Res 1985;41:533-542
4. Bottrill FE, Douglas SA, Hiley CR, White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 2000;130:1865-1870
5. Bousette N, Pottinger J, Ramli W, Ohlstein EH, Dhanak D, Douglas SA, et al. Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides 2006;27:2919-2926
6. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin Jr WG. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003;4:147-158
7. Chatenet D, Dubessy C, Leprince J, Boularan C, Carlier L, Ségalas-Milazzo I, et al. Structure-activity relationships and structural conformation of a novel urotensin II-related peptide. Peptides 2004;25:1819-1830
8. Dai HY, Ge ZM, Li YH. Effect of urotensin II on proliferative potential and phosphorylation of extracellular signal-regulated kinase 1/2 of adventitial fibroblasts from spontaneously hypertensive rat. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2006;28:776-780
9. Djordjevic T, BelAiba RS, Bonello S, Pfeilschifter J, Hess J, Görlach A. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 2005;25:519-525
10. Douglas SA. Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'? Curr Opin Pharmacol 2003;3:159-167
11. Douglas SA, Behm DJ, Aiyar NV, Naselsky D, Disa J, Brooks DP, et al. Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375. Br J Pharmacol 2005;145:620-635
12. Douglas SA, Ohlstein EH. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 2000;10:229-237
13. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 2000;131:1262-1274
14. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 2002;359:1990-1997
15. Finlay G. The LAM cell: what is it, where does it come from, and why does it grow? Am J Physiol Lung Cell Mol Physiol 2004;286:L690-3.
16. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. Expression of endothelin-1 in lungs of patients with pulmonary hypertension. N Eng J Med 1993;328:1732-1739
17. Gibson A. Complex effects of Gillichthys urotensin II on rat aortic strips. Br J Pharmacol 1987;91:205-212
18. Gray GA, Jones MR, Sharif I. Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition. Life Sci 2001;69:175-180
19. Hay DW, Luttmann MA, Douglas SA. Human urotensin-II is a potent spasmogen of primate airway smooth muscle. Br J Pharmacol 2000;131:10-12
20. He YH, Hong JM, Guo HS, Wei JR, Chen H, Zuo HH, et al. Effects of urotensin II on cultured cardiac fibroblast proliferation and collagen type I mRNA expression. Di Yi Jun Yi Da Xue Xue Bao 2004;24:505-508
21. Hillier C, Berry C, Petrie MC, O'Dwyer PJ, Hamilton C, Brown A, et al. Effects of urotensin II in human arteries and veins of varying caliber. Circulation 2001;103:1378-1381
22. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005;37:19-24.
23. Jegou S, Cartier D, Dubessy C, Gonzalez BJ, Chatenet D, Tostivint H, et al. Localization of the urotensin II receptor in the rat central nervous system. J Comp Neurol 2006;49:21-36.
24. Karbowniczek M, Astrinidis A, Balsara BR, Testa JR, Lium JH, Colby TV, et al. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 2003;167:976-982
25. Karbowniczek M, Cash T, Cheung M, Robertson GP, Astrinidis A, Henske. Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J Biol Chem 2004;279:29930-29937
26. KatanoY, Ishihata A, Aita T, Ogaki T, Horie T. Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors on rat coronary arteries. Eur J Pharmacol 2000;402:R5-7.
27. Lin L, Ding WH, Jiang W, Zhang YG, Qi YF, Yuan WJ, et al. Urotensin-II activates l-arginine/nitric oxide pathway in isolated rat aortic adventitia. Peptides 2004;25:1977-1984
28. Liu Q, Pong SS, Zeng Z, Zhang Q, Howard AD, Williams Jr DL, et al. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 1999;266:174-178
29. Liu GQ, Zeng ZP, Li HZ, Fan XR, Liu DM, Tong AL, et al. Expression of urotensin II mRNA in normal adrenal medulla and pheochromocytoma tissues. Zhonghua Yi Xue Za Zhi 2003;83:1225-1228
30. MacLean MR, Alexander D, Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, et al. Contractile responses tohumanurotensin-II in rat andhumanpulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 2000;130:201-204
31. Maguire JJ, Kuc RE, Davenport AP. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 2000;131:441-446
32. Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N, et al. Coexpression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 2001;19:2185-2190
33. Matsushita M, Shichiri M, Fukai N, Ozawa N, Yoshimoto T, Takasu N, et al. Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line, LLCPK1. Endocrinology 2003;144:1825-1831
34. Mori M, Sugo T, Abe M, Shimomura Y, Kurihara M, Kitada C, et al. Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). Biochem Biophys Res Commun 1999;265:123-129
35. Morimoto R, Satoh F, Murakami O, Totsune K, Arai Y, Suzuki T, et al. Immunolocalization of urotensin II and its receptor inhumanadrenal tumors and attached non-neoplastic adrenal tissues. Peptides 2008;29:873-880
36. Nothacker HP, Wang Z, McNeill AM, Saito Y, Merten S, O'Dowd B, et al. Identification of the natural ligand of an orphan G-protein coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol 1999;1:383-385
37. Pearson D, Shively JE, Clark BR, Geschwind II, Barkley M, Nishioka RS, et al. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci USA 1980;77:5021-5024
38. Rakowski E, Hassan G, Ohlstein EH, Douglas SA, Giaid A. A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker. J Mol Cell Cardiol 2005;39:785-791
39. Saito T, Hu F, Tayara L, Fahas L, Shennib H, Giaid A. Inhibition of NO synthase II prevents cardiac dysfunction in myocardial infarction and congestive heart failure. Am J Physiol: Heart and Circulatory Physiology 2002;283:H339-45.
40. Sauzeau V, Le Mellionnec E, Bertoglio J, Scalbert E, Pacaud P, Loirand G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 2001;88:1102-1104
41. Shenouda A, Douglas SA, Olstein EH, Giaid A. Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma. Histochem Cytochem 2002;50:885-890
42. Shi L, Ding W, Li D, Wang Z, Jiang H, Zhang J, et al. Proliferation and antiapoptotic effects of human urotensin II on human endothelial cells. Atherosclerosis 2006;188:260-264
43. Spinazzi R, Albertin G, Nico B, Guidolin D, Di Liddo R, Rossi GP, et al. Urotensin-II and its receptor (UT-R) are expressed in rat brain endothelial cells, and urotensin-II via UT-R stimulates angiogenesis in vivo and in vitro. Int J Mol Med 2006;18:1107-1112
44. Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, Berry C, Kirk A, et al. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 2001;280:H925-8.
45. Sugo T, Murakami Y, Shimomura Y, Harada M, Abe M, Ishibashi Y, et al. Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochem Biophys Res Commun 2003;310:860-868
46. Takahashi K, Totsune K, Kitamuro T, Sone M, Murakami O, Shibahara S. Three vasoactive peptides, endothelin-1, adrenomedullin and urotensin-II, in human tumour cell lines of different origin: expression and effects on proliferation. Clin Sci (Lond) 2002;103:S35-8.
47. Takahashi K, Totsune K, Murakami O, Arihara Z, Noshiro T, Hayashi Y, et al. Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II. Peptides 2003;24:301-306
48. Taveira-DaSilva AM, Hathaway OM, Sachdev V, Shizukuda Y, Birdsall CW, Moss J. Pulmonary artery pressure in lymphangioleiomyomatosis: an echocardiographic study. Chest 2007;132:1573-1578
49. Watanabe T, Pakala R, Katagiri T, Benedict CR. Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J Hypertens 2001;19:2191-2196
50. Zeng ZP, Liu GQ, Li HZ, Fan XR, Liu DM, Tong AL, et al. The effects of urotensin-II on proliferation of pheochromocytoma cells and mRNA expression of urotensin-II and its receptor in pheochromocytoma tissues. Ann NY Acad Sci 2006;1073:284-289